The University of Southampton
University of Southampton Institutional Repository

The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients

The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients
The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients
The objective of this study was to compare the inflammatory marker eosinophil cationic protein (ECP) with peak expiratory flow (PEF) in determining the therapeutic needs of inhaled corticosteroids in asthma patients assessed as asthma symptoms. A randomized, single-blind study over 6 months was performed at six specialist centres in Europe. In total, 164 adult patients with moderate to severe symptomatic asthma and regular use of inhaled corticosteroids were included. After a run-in period of 2 weeks patients were randomly allocated to the ECP or the PEF monitoring group. The dose of inhaled corticosteroids was adjusted every fourth week based on the current serum ECP value or pre-broncho-dilator morning PEF values as surrogate markers of therapeutic needs. At the end of the study there were no statistically significant differences in the mean daily symptom score or the percentage of symptom-free days between the two groups. The mean daily dose of inhaled corticosteroids was similar in the two groups at the start of the study but the algorithms used to adjust the dose of inhaled corticosteroids resulted in an increased use of inhaled corticosteroids in both groups. The mean daily dose of inhaled corticosteroids over the whole study period was significantly lower in the ECP group compared with the PEF group (1246 vs. 1667 µg,P =0·026). In the ECP group, forced expiratory volume in 1 sec (FEV1)% predicted was lower at the end of the study compared with the beginning (92% vs. 87%, P=0·0009), although there was no significant difference between the two groups. None of the used algorithms for ECP and PEF led to improvement in symptom scores, in spite of increased doses of inhaled corticosteroids. In this respect, both methods were equivalent and insufficient. Recommendations suggesting lung function tests in current guidelines may be difficult to translate into clinical practice, however, a combination of inflammatory markers, lung function and symptoms may still improve asthma control.
asthma, corticosteroids, eosinophil cationic protein, inflammation, pef
95-101
Löwhagen, O.
75c15b81-33d2-4e73-a2f6-4bf173b713b4
Wever, A.M.J.
efd76a07-5717-4e2a-9b5e-ad0b1f93b8c4
Lusuardi, M.
981ebb6f-3f28-4a38-91c8-663bcbd0a3d5
Moscato, G.
41e49653-658d-4671-a00f-70e2069e16da
De Backer, W.A.
5ed3797a-f99b-4f21-a14f-d3865a96355f
Gandola, L.
5bf8b49e-5cfe-453a-9823-550f045c5472
Donner, C.F.
befb1fea-8ed5-4810-9b86-23c0bdee3f2c
Ahlstedt, S.
42b4ca6b-2495-4a17-b3e0-674193d8b845
Larsson, L.
95d52edc-6482-4cb2-86bb-1f7e7cbf72f9
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Löwhagen, O.
75c15b81-33d2-4e73-a2f6-4bf173b713b4
Wever, A.M.J.
efd76a07-5717-4e2a-9b5e-ad0b1f93b8c4
Lusuardi, M.
981ebb6f-3f28-4a38-91c8-663bcbd0a3d5
Moscato, G.
41e49653-658d-4671-a00f-70e2069e16da
De Backer, W.A.
5ed3797a-f99b-4f21-a14f-d3865a96355f
Gandola, L.
5bf8b49e-5cfe-453a-9823-550f045c5472
Donner, C.F.
befb1fea-8ed5-4810-9b86-23c0bdee3f2c
Ahlstedt, S.
42b4ca6b-2495-4a17-b3e0-674193d8b845
Larsson, L.
95d52edc-6482-4cb2-86bb-1f7e7cbf72f9
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc

Löwhagen, O., Wever, A.M.J., Lusuardi, M., Moscato, G., De Backer, W.A., Gandola, L., Donner, C.F., Ahlstedt, S., Larsson, L. and Holgate, S.T. (2002) The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients. Respiratory Medicine, 96 (2), 95-101. (doi:10.1053/rmed.2001.1218).

Record type: Article

Abstract

The objective of this study was to compare the inflammatory marker eosinophil cationic protein (ECP) with peak expiratory flow (PEF) in determining the therapeutic needs of inhaled corticosteroids in asthma patients assessed as asthma symptoms. A randomized, single-blind study over 6 months was performed at six specialist centres in Europe. In total, 164 adult patients with moderate to severe symptomatic asthma and regular use of inhaled corticosteroids were included. After a run-in period of 2 weeks patients were randomly allocated to the ECP or the PEF monitoring group. The dose of inhaled corticosteroids was adjusted every fourth week based on the current serum ECP value or pre-broncho-dilator morning PEF values as surrogate markers of therapeutic needs. At the end of the study there were no statistically significant differences in the mean daily symptom score or the percentage of symptom-free days between the two groups. The mean daily dose of inhaled corticosteroids was similar in the two groups at the start of the study but the algorithms used to adjust the dose of inhaled corticosteroids resulted in an increased use of inhaled corticosteroids in both groups. The mean daily dose of inhaled corticosteroids over the whole study period was significantly lower in the ECP group compared with the PEF group (1246 vs. 1667 µg,P =0·026). In the ECP group, forced expiratory volume in 1 sec (FEV1)% predicted was lower at the end of the study compared with the beginning (92% vs. 87%, P=0·0009), although there was no significant difference between the two groups. None of the used algorithms for ECP and PEF led to improvement in symptom scores, in spite of increased doses of inhaled corticosteroids. In this respect, both methods were equivalent and insufficient. Recommendations suggesting lung function tests in current guidelines may be difficult to translate into clinical practice, however, a combination of inflammatory markers, lung function and symptoms may still improve asthma control.

This record has no associated files available for download.

More information

Published date: 2002
Keywords: asthma, corticosteroids, eosinophil cationic protein, inflammation, pef

Identifiers

Local EPrints ID: 27238
URI: http://eprints.soton.ac.uk/id/eprint/27238
PURE UUID: a7ac6e0d-aa74-4fa9-a871-b14168bdce44

Catalogue record

Date deposited: 28 Apr 2006
Last modified: 15 Mar 2024 07:16

Export record

Altmetrics

Contributors

Author: O. Löwhagen
Author: A.M.J. Wever
Author: M. Lusuardi
Author: G. Moscato
Author: W.A. De Backer
Author: L. Gandola
Author: C.F. Donner
Author: S. Ahlstedt
Author: L. Larsson
Author: S.T. Holgate

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×